Northwest Biotherapeutics Announces $15 Million Financing
PUBLIC · NWBONov 29, 2021
Amount Raised
$15 Million
Round Type
Funding Round
BethesdaBiotechnologyHealthcareresearch
Description
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of a $15 million financing on November 22, 2021, which brought the Company's cash reserves above $20 million.
Who to call at Northwest Biotherapeutics, and when
A new round usually means Northwest Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Northwest Biotherapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Northwest Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Northwest Biotherapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Northwest Biotherapeutics
Location
4800 MONTGOMERY LANE,
Bethesda, Maryland, United States
About
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." This Phase III trial reached data lock and the Company is actively continuing to move toward announcement of top line data. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Northwest Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BethesdaBiotechnologyHealthcareresearch